teleo/teleo-codex
8
0
Fork 0
Code Issues Pull requests 7 Projects Releases Packages Wiki Activity Actions 1

Merge pull request #21 from living-ip/vida/nav-layer-fixes

Browse source 
Vida navigation layer: pipe-alias fix. 0 broken links across health domain.
This commit is contained in:
m3taversal 2026-03-06 06:07:48 -07:00 committed by GitHub
commit d754b41f1c
No known key found for this signature in database
GPG key ID: B5690EEEBB952194
1 changed files with 1 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

2
domains/health/Oura controls 80 percent of the smart ring market with patent-defended form factor while a demographic pivot from fitness enthusiasts to wellness-focused women drives 250 percent sales growth.md
View file

@ -17,7 +17,7 @@ The retention data validates the pivot: 12-month retention in the high-80s, comp
Oura is actively defending its position through patent litigation. In November 2025, it filed ITC complaints against Samsung (Galaxy Ring), Reebok, Amazfit, and Luna for form factor patent infringement. Samsung's attempt to invalidate Oura's core patent at PTAB failed. The strategic question is whether these patents create a durable moat or merely slow competitors.
Three acquisitions in two years signal platform ambitions beyond the ring: Proxy (identity/auth, 2023), Veri (CGM app, 2024), and Sparta Science (enterprise analytics, 2024). The Veri acquisition is especially significant -- it positions Oura to integrate continuous glucose monitoring into its ring data platform, moving toward the [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware|multi-layer sensor stack convergence]] already documented in the health landscape.
Three acquisitions in two years signal platform ambitions beyond the ring: Proxy (identity/auth, 2023), Veri (CGM app, 2024), and Sparta Science (enterprise analytics, 2024). The Veri acquisition is especially significant -- it positions Oura to integrate continuous glucose monitoring into its ring data platform, moving toward the [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]] already documented in the health landscape.
The key risk is valuation: $11B at ~22x revenue is aggressive. A tender offer at 25% discount suggests some secondary market participants see it as stretched. The Samsung patent battle outcome remains uncertain despite early wins. And the Palantir/DoD privacy controversy (August 2025), while factually overblown, demonstrated consumer sensitivity around biometric data governance.